玛莱克琳生物技术公司Moleculin Biotech, Inc.（MBRX） 2025年公司介绍：投资者演示报告「NASDAQ」（英文版）（31页）.pdf

1、NASDAQ:MBRX|NASDAQ:MBRX|May May 20252025Corporate Corporate PresentationPresentationDisclaimerDisclaimerAll statements contained herein other than statements of historical fact,including statements regarding our future results of operations and financial position,our business strategy and plans,and

2、our objectives for future operations,are forward-looking statements.The words“believe,”“may,”“will,”“estimate,”“continue,”“anticipate,”“intend,”“expect,”and similar expressions are intended to identify forward-looking statements.We have based these forward-lookingstatements largely on our current ex

3、pectations and projections about future events and trends that we believe may affect our financial condition,results ofoperations,business strategy,short-term and long-term business operations and objectives,and financial needs.Our potential to sustain our relationship withMD Anderson revolves aroun

4、d the continued collaboration and capitalizing on intellectual property resulting from sponsored research.The feasibility andpromptness of our clinical trials are influenced by regulatory stipulations from entities like the US Food&Drug Administration(FDA)and their globalcounterparts.As such,all of

5、our trials,including the MIRACLE trial,are subject to timely,future filings with and feedback,allowance,approvals,etc.from the FDAand their global counterparts.The implications of global events,such as the conflict in Ukraine,the COVID-19 pandemic,and prevalent supply chain challenges,play a role in

6、 our forward-looking statements.We will require significant additional financing,for which we have no commitments,in order to conduct our clinicaltrials as described in this presentation,and the milestones described in this presentation assume our ability to secure such financing on a timely basis.A